Detalhe da pesquisa
1.
Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial.
J Urol
; : 101097JU0000000000003999, 2024 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38708869
2.
Comparative analysis of real-world adherence and persistence patterns with vibegron, mirabegron, and anticholinergics in patients with overactive bladder: A retrospective claims study.
Neurourol Urodyn
; 2024 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38720543
3.
Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial.
Int J Clin Pract
; 2022: 6475014, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35685566
4.
Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR).
J Urol
; 205(5): 1421-1429, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33356445
5.
Vibegron improves quality-of-life measures in patients with overactive bladder: Patient-reported outcomes from the EMPOWUR study.
Int J Clin Pract
; 75(5): e13937, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33332699
6.
International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR.
J Urol
; 204(2): 316-324, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32068484
7.
Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS).
J Urol
; 203(6): 1163-1171, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31895002
8.
Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR).
BMC Geriatr
; 20(1): 109, 2020 03 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32183741
9.
Feasibility of a Fully Implanted, Nickel Sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary Incontinence.
J Urol
; 201(5): 967-972, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31009968
10.
Effect of Pharmacotherapy for Overactive Bladder on the Incidence of and Factors Related to Urinary Tract Infection: A Systematic Review and Meta-analysis. Letter.
J Urol
; 210(1): 31-32, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37126235
11.
Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients.
Neurourol Urodyn
; 37(1): 394-406, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28704584
12.
Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).
Health Qual Life Outcomes
; 16(1): 69, 2018 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29673355
13.
A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study).
Int Urogynecol J
; 29(2): 273-283, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28620791
17.
Validation of a bladder symptom screening tool in women with incontinence due to overactive bladder.
Int Urogynecol J
; 25(12): 1655-63, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24859795
18.
Oxybutynin-associated Cognitive Impairment: Evidence and Implications for Overactive Bladder Treatment.
Urology
; 186: 123-129, 2024 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38296001
19.
Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis.
Adv Ther
; 41(5): 2086-2097, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38520502
20.
The evaluation and treatment of prostate-related LUTS in the primary care setting: the next STEP.
Curr Urol Rep
; 14(6): 595-605, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24026361